News & Press
Kernel announces first commercial fNIRS drug efficacy study partnership with Pfizer
Reuters Health4/6/2026·04/06/26🌐 USA
Summary
Kernel announced a multi-year partnership with Pfizer to use the Kernel Flow 2 wearable fNIRS system as a pharmacodynamic biomarker in three Phase 2 CNS drug trials. The partnership validates neuroimaging-as-a-biomarker for pharmaceutical development and represents Kernel's largest commercial deal to date, valued at over $15M.
Why it matters
A Pfizer partnership worth $15M+ validates Kernel's pivot from consumer BCI to pharmaceutical research tool. This deal demonstrates that wearable neuroimaging has crossed the threshold from research curiosity to commercially valuable drug development infrastructure.
#BCI#Neuroimaging#Neuropharmacology#Wearables
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trialAlready a member? Sign in